Welcome to our dedicated page for Biote SEC filings (Ticker: BTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biote Corp. (NASDAQ: BTMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, earnings-related materials and other documents filed with the U.S. Securities and Exchange Commission. Biote is a preventive health care solutions provider focused on personalized hormone optimization and therapeutic wellness, and its filings offer detailed insight into this business.
Biote’s filings include Forms 8-K that furnish press releases on quarterly financial results and material events. For example, the company has filed an 8-K to report financial results for the quarter ended September 30, 2025, attaching the full earnings press release as an exhibit. These documents summarize revenue trends, procedure and dietary supplement revenue, gross profit margins, operating income, net income and non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDA margin.
Through its periodic reports, investors can review information on Biote’s revenue mix, cost structure and capital allocation, including references to share repurchase programs and settlement-related share repurchases. The company also explains how it calculates non-GAAP metrics and outlines the limitations of these measures compared with GAAP results.
On Stock Titan, Biote’s SEC filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the main drivers of performance, changes in guidance and significant corporate actions. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while structured access makes it easier to locate earnings materials and other regulatory disclosures for BTMD.
Biote Corp. reported first quarter 2026 revenue of $44.9 million, down 8.3% from $49.0 million, as procedure volumes were hurt by a voluntary recall of certain hormone pellet products. Gross margin slipped to 68.9% from 74.3%, and operating income fell to $3.2 million from $9.7 million.
Net income declined to $2.7 million (diluted EPS $0.06) from $15.8 million ($0.37), largely because the gain from changes in earnout liabilities dropped to $2.1 million from $10.7 million. Adjusted EBITDA was $8.7 million, a 36.6% decrease, with margin down to 19.4% from 28.1%.
Dietary supplements revenue grew 19.1% to $11.0 million, partly offsetting a 13.2% decline in procedure revenue to $31.3 million. Management reaffirmed 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million, and continues to expect procedure revenue to return to growth in the second half of 2026.
biote Corp. reported that General Counsel Daniel Michael Monico received a grant of 88,800 employee stock options for Class A common stock at an exercise price of $2.19 per share. Following the grant, he holds 88,800 options directly.
One-half of the options vest on April 27, 2028, with the remaining half vesting in 24 equal monthly installments after that date, contingent on his continued service. The options expire on April 30, 2036. This is a compensation-related award, not an open‑market purchase or sale.
biote Corp. filed an initial Form 3 showing that General Counsel Daniel Michael Monico beneficially owns 1 share of Class A Common Stock. The filing reports this direct holding as of April 27, 2026 and does not reflect any buy or sell transaction.
biote Corp. filed a report to share an updated investor presentation that outlines its 2025 performance and 2026 outlook. For 2025, the company reports revenue of $192.2 million and Adjusted EBITDA of $53.5 million, reflecting a 27.8% Adjusted EBITDA margin. The presentation also provides 2026 guidance, targeting revenue above $190 million and Adjusted EBITDA above $38 million, and describes Biote’s strategy to expand its hormone optimization and broader therapeutic wellness offerings through a scalable practitioner network and proprietary technology platform.
biote Corp. reported that Chief Executive Officer Bret Christensen received a grant of employee stock options. The award covers 441,653 options to buy Class A Common Stock at an exercise price of $1.43 per share, all held as direct ownership.
According to the vesting terms, 25% of the options will vest on April 1, 2027. The remaining options will then vest in 36 substantially equal monthly installments, contingent on Christensen’s continuous service through each vesting date. No open‑market purchases or sales were reported in this filing.
biote Corp. Chief Financial Officer Robert Charles Peterson received a grant of 107,169 employee stock options for Class A Common Stock. The options have an exercise price of $1.43 per share and expire on March 31, 2036.
After this award, Peterson holds 107,169 derivative securities. According to the vesting schedule, 25% of the options vest on April 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, contingent on his continued service.
Biote Corp. is holding its 2026 annual stockholder meeting virtually on May 12, 2026 at 10:00 a.m. Central Time via webcast at www.proxydocs.com/BTMD. Holders of Class A and Class V common stock as of March 23, 2026 may attend, vote, and submit questions online.
Stockholders will vote on electing two Class I directors and ratifying Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026. The proxy also details board composition, committee structures, governance policies, and executive and director compensation, including stock option awards and bonus decisions tied to 2025 corporate performance goals.
biote Corp. files its 2025 annual report, reporting revenue of $192.2 million and net income of $31.6 million. Revenue was slightly below 2024’s $197.2 million, but profitability improved sharply. The company operates a hormone optimization practice-building platform and a Biote-branded dietary supplements line, serving over 9,200 practitioners in more than 5,300 clinics.
Dietary supplements contributed about 22% of 2025 revenue, and procedure-based service fees about 71%. biote highlights a large, growing hormone replacement therapy market, strong practitioner retention above 91%, and an all-cash model designed to support attractive practice economics while navigating significant regulatory oversight of supplements and compounded hormones.
Biote Corp. reported 2025 revenue of $192.2 million, down 2.5% from 2024, as procedure revenue declined 8.8% while dietary supplements grew 19.1%. Gross margin improved to 71.5%, and operating income rose 12.5% to $35.6 million helped by lower operating expenses from a sales reorganization.
Net income jumped to $31.6 million (diluted EPS $0.74) from $0.05 million (EPS $0.09), largely influenced by a $13.0 million gain from changes in earnout liabilities. Adjusted EBITDA declined 8.1% to $53.5 million, with margin slipping to 27.8%. For 2026, Biote guides revenue to above $190 million and Adjusted EBITDA above $38 million, reflecting a planned step-up in sales and technology investments, with procedure revenue expected to fall in the first half before returning to growth in the second half.